9 results about "Platelet receptor" patented technology

The present invention relates to the field of immunochromatographic detection, and specifically to an immunochromatographic detection kit for platelet P2Y12 receptor inhibition rate, a preparation method, and a detection method. The kit comprises: a test strip A and a sample diluent, or in test strip A: the sample diluent, the sample pad, and / or the conjugate pad contain fluorescently labeled platelet surface-specific receptor antibodies, anti-erythrocyte antibodies, ADP, and prostaglandin E1; and a test strip B and a sample diluent, or in test strip B: the sample diluent and / or the sample-conjugate pad contain fluorescently labeled platelet surface-specific receptor antibodies, anti-erythrocyte antibodies, ADP, and prostaglandin E1. The kit has high detection accuracy and specificity, and a comparative test with the "gold standard" turbidimetric method (LTA method) showed that the detection results of the present invention were well consistent with those of the "gold standard."

This invention relates to an antibody or antigen-binding fragment of phosphorylated VASP-Ser 239 protein and its applications. The antibody comprises specific light and heavy chain variable region complementarity-determining region (CDR) sequences or amino acid sequences having at least 80% sequence identity with them. The invention also provides isolated polynucleotides encoding the antibody, expression vectors, recombinant cells, and methods for preparing the antibody. The antibody and its derivatives of this invention can efficiently and specifically detect phosphorylated VASP-Ser 239 protein in human whole blood or platelet cells, and are suitable for monitoring the inhibitory effect of platelet ADP receptor (P2Y12) antagonists (such as clopidogrel) on platelet activation, clarifying clopidogrel resistance, and guiding rational clinical drug use. This invention solves the current shortage of antibody raw materials and kits for related detection projects on the market.

The invention relates to a phosphorylated VASP-Ser 239 protein antibody or an antigen binding fragment and application thereof. The antibody comprises specific light chain and heavy chain variable region complementarity determining region (CDR) sequences or amino acid sequences with at least 80% sequence identity with the CDR sequences. The invention also provides isolated polynucleotide for coding the antibody, an expression vector, a recombinant cell and a method for preparing the antibody. The antibody and derivative products thereof can efficiently and specifically detect phosphorylated VASP-Ser 239 protein in human whole blood or platelet cells, and are suitable for monitoring the inhibition effect of a platelet ADP receptor (P2Y12) antagonist (such as clopidogrel) on platelet activation, determining the clopidogrel resistance situation and guiding clinical reasonable medication. The invention solves the problem of shortage of antibody raw materials and kits of related detection items in the current market.

The present invention relates to the field of immunochromatographic detection, and specifically relates to an immunochromatographic detection kit for the inhibition rate of platelet GP IIb / IIIa receptor, a preparation method and a detection method, including: in the test strip A and the sample diluent: the sample diluent, the sample pad and / or the conjugate pad contain fluorescently labeled platelet surface specific receptor antibodies, anti-red blood cell antibodies, thrombin receptor I activating peptide and thrombin receptor IV activating peptide; in the test strip B and the sample diluent: the sample diluent and / or the sample-conjugate integrated pad contain fluorescently labeled platelet surface specific receptor antibodies, anti-red blood cell antibodies, thrombin receptor I activating peptide and thrombin receptor IV activating peptide; the above-mentioned kit has high detection accuracy, and has been compared with the "gold standard" turbidimetry (LTA method). The comparison results show that: the detection results of the present invention are in good agreement with the "gold standard".

The present invention provides engineered platelets having a chimeric platelet receptor (CPR) with desired target specificity. Furthermore, the engineered platelets may contain cargo that can be released upon platelet activation. In addition, the platelets can be generated in vitro from megakaryocytes engineered to produce non-thrombotic platelets. [Solution] To provide an engineered megakaryocyte or precursor capable of reducing thrombogenic ability and / or producing platelets with reduced thrombogenic ability, comprising the disruption or deletion of at least one gene encoding a protein involved in the recognition of a primary stimulus for thrombosis, one gene encoding a protein involved in the recognition of a secondary mediator for thrombosis, and one gene encoding a protein involved in the release of a secondary mediator for thrombosis.

The invention relates to a phosphorylated VASP-Ser 157 protein antibody or an antigen binding fragment and application thereof. The antibody comprises specific light chain and heavy chain variable region complementarity determining region (CDR) sequences. The antibody has high affinity and specificity, is suitable for preparing a phosphorylated VASP-Ser 157 protein detection product, and comprises a kit and a conjugate. The invention also provides isolated polynucleotide, an expression vector and a recombinant cell for coding the antibody. The antibody and derivative products thereof can specifically detect phosphorylated VASP-Ser 157 protein in human whole blood or platelet cells, and are suitable for monitoring the inhibition effect of a platelet ADP receptor (P2Y12) antagonist (such as clopidogrel) on platelet activation, determining the clopidogrel resistance situation and guiding clinical reasonable medication.

The present invention relates to an antibody or antigen-binding fragment of phosphorylated VASP-Ser 157 protein and its application, wherein the antibody comprises specific light chain and heavy chain variable region complementary determining region (CDR) sequences. The antibody has high affinity and specificity and is suitable for preparing detection products for phosphorylated VASP-Ser 157 protein, including kits and conjugates. The present invention also provides isolated polynucleotides, expression vectors, and recombinant cells encoding the antibody. The antibodies and derivatives thereof of the present invention can specifically detect phosphorylated VASP-Ser 157 protein in human whole blood or platelet cells, and are suitable for monitoring the inhibitory effect of platelet ADP receptor (P2Y12) antagonists (such as clopidogrel) on platelet activation, clarifying clopidogrel resistance, and guiding rational clinical drug use.

The invention relates to the field of human immunity, and particularly discloses a monoclonal antibody for recognizing platelet membrane glycoprotein and application of the monoclonal antibody in antithrombotic treatment. Monoclonal antibodies R813 and Y262 acting on different sites of a platelet receptor GP IIb-IIIa are developed, the monoclonal antibodies can well inhibit platelet aggregation, the two antibodies are combined to form the cocktail, the functions of the platelet receptor GP IIb-IIIa can be completely blocked, the platelet aggregation function is thoroughly inhibited, and the cocktail can be used for preparing the cocktail. The cocktail biological activity of the monoclonal antibody exceeds that of an antiplatelet drug Reopro, and the dosage is small; the antibody is prepared into an F (ab ') 2 fragment by an enzymolysis method, so that the molecular weight of the antibody is reduced while the biological activity is preserved, the amount of the antibody reaching an action target site is increased, the Fc terminal is removed, the HAMA reaction is reduced, and the platelet destruction caused by combination with a reticuloendothelial system is reduced. In addition, the enzymolysis method is simple to operate, low in cost and convenient for batch preparation and production of antibody fragments.

The application belongs to the technical fields of polypeptide and biological medicine, and particularly relates to a polypeptide SR14 and application thereof. The amino acid sequence of the polypeptide SR14 is SCEPCQTLAVRSYR. The polypeptide SR14 composed of the amino acids can be effectively combined with a platelet receptor, interfere with the aggregation of thrombin-activated platelets, and then achieve the effect of anti-thrombus. Meanwhile, the polypeptide SR14 has a low risk of bleeding, and can be used for the preparation of anti-thrombus drugs.